Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total		Initial Public Offering	Private Placement	Common Stock	Common Stock Initial Public Offering	Common Stock Private Placement	Additional Paid-In Capital	Additional Paid-In Capital Initial Public Offering	Additional Paid-In Capital Private Placement	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Series C Redeemable Convertible Preferred Stock
Balance at beginning of period (in shares) at Dec. 31, 2019													56,000,000	49,501,221	26,360,745
Balance at beginning of period at Dec. 31, 2019													$ 62,468	$ 75,860	$ 47,947
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series C redeemable preferred stock, net of issuance costs (in shares)															28,527,313
Issuance of Series C redeemable preferred stock, net of issuance costs															$ 52,038
Balance at end of period (in shares) at Mar. 31, 2020													56,000,000	49,501,221	54,888,058
Balance at end of period at Mar. 31, 2020													$ 62,468	$ 75,860	$ 99,985
Balance at beginning of period (in shares) at Dec. 31, 2019					1,846,024
Balance at beginning of period at Dec. 31, 2019	$ (76,295)				$ 1			$ 0			$ (1)	$ (76,295)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)					52,093
Vesting of restricted stock awards	4							4
Option exercises (in shares)					8,232
Option exercises	26							26
Stock-based compensation expense	425							425
Net unrealized gain on short-term investments	60										60
Net income (loss)	11,029											11,029
Balance at end of period (in shares) at Mar. 31, 2020					1,906,349
Balance at end of period at Mar. 31, 2020	(64,751)				$ 1			455			59	(65,266)
Balance at beginning of period (in shares) at Dec. 31, 2019													56,000,000	49,501,221	26,360,745
Balance at beginning of period at Dec. 31, 2019													$ 62,468	$ 75,860	$ 47,947
Balance at end of period (in shares) at Jun. 30, 2020													0	0	0
Balance at end of period at Jun. 30, 2020													$ 0	$ 0	$ 0
Balance at beginning of period (in shares) at Dec. 31, 2019					1,846,024
Balance at beginning of period at Dec. 31, 2019	(76,295)				$ 1			0			(1)	(76,295)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized gain on short-term investments	(29)
Net income (loss)	(5,972)
Balance at end of period (in shares) at Jun. 30, 2020					35,427,199
Balance at end of period at Jun. 30, 2020	315,816				$ 3			398,110			(30)	(82,267)
Balance at beginning of period (in shares) at Mar. 31, 2020													56,000,000	49,501,221	54,888,058
Balance at beginning of period at Mar. 31, 2020													$ 62,468	$ 75,860	$ 99,985
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of Series A, B, C convertible preferred stock to common stock (in shares)													(56,000,000)	(49,501,221)	(54,888,058)
Conversion of Series A, B, C convertible preferred stock to common stock													$ (62,468)	$ (75,860)	$ (99,985)
Balance at end of period (in shares) at Jun. 30, 2020													0	0	0
Balance at end of period at Jun. 30, 2020													$ 0	$ 0	$ 0
Balance at beginning of period (in shares) at Mar. 31, 2020					1,906,349
Balance at beginning of period at Mar. 31, 2020	(64,751)				$ 1			455			59	(65,266)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common/preferred stock (in shares)						10,350,000	625,000
Issuance of common/preferred stock			$ 148,400	$ 10,000		$ 1			$ 148,399	$ 10,000
Vesting of restricted stock awards (in shares)					40,102
Vesting of restricted stock awards	1							1
Option exercises (in shares)					73,719
Option exercises	177							177
Conversion of Series A, B, C convertible preferred stock to common stock (in shares)					22,432,029
Conversion of Series A, B, C convertible preferred stock to common stock	238,293				$ 1			238,292
Stock-based compensation expense	786							786
Net unrealized gain on short-term investments	(89)										(89)
Net income (loss)	(17,001)											(17,001)
Balance at end of period (in shares) at Jun. 30, 2020					35,427,199
Balance at end of period at Jun. 30, 2020	$ 315,816				$ 3			398,110			(30)	(82,267)
Balance at beginning of period (in shares) at Dec. 31, 2020													0	0	0
Balance at beginning of period at Dec. 31, 2020													$ 0	$ 0	$ 0
Balance at end of period (in shares) at Mar. 31, 2021													0	0	0
Balance at end of period at Mar. 31, 2021													$ 0	$ 0	$ 0
Balance at beginning of period (in shares) at Dec. 31, 2020	35,552,795				35,552,795
Balance at beginning of period at Dec. 31, 2020	$ 283,061	[1]			$ 3			400,918			(32)	(117,828)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)					30,277
Vesting of restricted stock awards	2							2
Option exercises (in shares)					165,264
Option exercises	1,370							1,370
Stock-based compensation expense	2,578							2,578
Net unrealized gain on short-term investments	14										14
Net income (loss)	(22,856)											(22,856)
Balance at end of period (in shares) at Mar. 31, 2021					35,748,336
Balance at end of period at Mar. 31, 2021	$ 264,169				$ 3			404,868			(18)	(140,684)
Balance at beginning of period (in shares) at Dec. 31, 2020													0	0	0
Balance at beginning of period at Dec. 31, 2020													$ 0	$ 0	$ 0
Balance at end of period (in shares) at Jun. 30, 2021													0	0	0
Balance at end of period at Jun. 30, 2021													$ 0	$ 0	$ 0
Balance at beginning of period (in shares) at Dec. 31, 2020	35,552,795				35,552,795
Balance at beginning of period at Dec. 31, 2020	$ 283,061	[1]			$ 3			400,918			(32)	(117,828)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized gain on short-term investments	2
Net income (loss)	$ (45,687)
Balance at end of period (in shares) at Jun. 30, 2021	35,853,916				35,853,916
Balance at end of period at Jun. 30, 2021	$ 243,980				$ 3			407,522			(30)	(163,515)
Balance at beginning of period (in shares) at Mar. 31, 2021													0	0	0
Balance at beginning of period at Mar. 31, 2021													$ 0	$ 0	$ 0
Balance at end of period (in shares) at Jun. 30, 2021													0	0	0
Balance at end of period at Jun. 30, 2021													$ 0	$ 0	$ 0
Balance at beginning of period (in shares) at Mar. 31, 2021					35,748,336
Balance at beginning of period at Mar. 31, 2021	264,169				$ 3			404,868			(18)	(140,684)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)					30,136
Vesting of restricted stock awards	2							2
Option exercises (in shares)					75,444
Option exercises	372							372
Stock-based compensation expense	2,280							2,280
Net unrealized gain on short-term investments	(12)										(12)
Net income (loss)	$ (22,831)											(22,831)
Balance at end of period (in shares) at Jun. 30, 2021	35,853,916				35,853,916
Balance at end of period at Jun. 30, 2021	$ 243,980				$ 3			$ 407,522			$ (30)	$ (163,515)

[1] The condensed balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.